|
1 |
Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases and enable development of multitarget therapeutics
Enthalten in Nature biomedical engineering 13.6.2025: 1-21
|
|
|
|
2 |
A double-blind, randomised, placebo-controlled parallel study to investigate the effect of sex and dietary nitrate on COVID-19 vaccine-induced vascular dysfunction in healthy men and women: protocol of the DiNOVasc-COVID-19 study
Enthalten in Trials Bd. 24, 16.9.2023, Nr. 1, date:12.2023: 1-14
|
|
|
|
3 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
Enthalten in BMC infectious diseases Bd. 20, 20.7.2020, Nr. 1, date:12.2020: 1-12
|
|
|
|
4 |
Achieving equitable recruitment through inclusive protocol design: lessons learned from the ILANA study
Enthalten in Trials Bd. 26, 1.7.2025, Nr. 1, date:12.2025: 1-8
|
|
|
|
5 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
Enthalten in AIDS research and therapy Bd. 16, 29.8.2019, Nr. 1, date:12.2019: 1-11
|
|
|
|
6 |
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV
Enthalten in Infectious diseases and therapy Bd. 14, 15.4.2025, Nr. 6, date:6.2025: 1201-1217
|
|
|
|
7 |
“If that would have lessened my symptoms, that would have been great...”: a qualitative study about the acceptability of tecovirimat as treatment for mpox
Enthalten in BMC medicine Bd. 23, 21.1.2025, Nr. 1, date:12.2025: 1-11
|
|
|
|
8 |
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Enthalten in AIDS research and therapy Bd. 22, 7.4.2025, Nr. 1, date:12.2025: 1-11
|
|
|
|
9 |
Mpox stigma in the UK and implications for future outbreak control: a cross-sectional mixed methods study
Enthalten in BMC medicine Bd. 23, 15.7.2025, Nr. 1, date:12.2025: 1-15
|
|
|
|
10 |
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
Enthalten in Virology journal Bd. 22, 10.2.2025, Nr. 1, date:12.2025: 1-11
|
|
Administration
